Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with/without modulators treatment.
Eur Radiol
August 2024
Univ. Bordeaux, INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, CIC 1401, F-33600, Pessac, France.
Objectives: Holistic segmentation of CT structural alterations with 3D deep learning has recently been described in cystic fibrosis (CF), allowing the measurement of normalized volumes of airway abnormalities (NOVAA-CT) as an automated quantitative outcome. Clinical validations are needed, including longitudinal and multicenter evaluations.
Materials And Methods: The validation study was retrospective between 2010 and 2023.
Allergic broncho-pulmonary aspergillosis: Old disease, new frontiers.
Respirology
August 2024
Allergy, Asthma & Clinical Immunology Service, The Alfred Hospital, Melbourne, Victoria, Australia.
Subacute invasive pulmonary aspergillosis in a nondiabetic immunocompetent female suffering from allergic broncho pulmonary aspergillosis.
J Family Med Prim Care
November 2023
Department of Microbiology, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India.
A 55-year-old female presented with recent exacerbation of the chronic cough, dyspnea, and copious expectoration. The symptoms worsened during the winter months. In the past, she was misdiagnosed with pulmonary tuberculosis.
View Article and Find Full Text PDFA Case of Allergic Bronchopulmonary Aspergillosis With Bronchial Asthma.
Cureus
September 2022
Internal Medicine, Lala Lajpat Rai (LLR) Hospital, Kanpur, IND.
Allergic bronchopulmonary aspergillosis (ABPA) is a fungal hypersensitivity reaction in chronic lung diseases like bronchial asthma and cystic fibrosis. It is caused by an allergic reaction to aspergillus antigen in the lung mucus resulting in airway inflammation and damage. This condition usually presents in a patient with asthma as a poorly controlled disease with recurrent infection symptoms that do not respond to standard antibiotic therapy.
View Article and Find Full Text PDFDiagnostic and therapeutic approach to fungal pneumonia in the critically ill patient.
Rev Esp Quimioter
April 2022
Jesús Fortún, Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Aspergillus spp. is the fungus most frequently producing ventilator-associated pneumonia (VAP), constituting 8% of them. This risk is significantly increased in onco-hematological patients: solid organ transplant recipients, chronic obstructive pulmonary disease (COPD), corticotherapy, cirrhosis, solid cancer, or viral pneumonias.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!